www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Share Buy-Back in ALK - week 31

July 31, 2012

PDF Version

Supporting Materials:
AT_W31_UK_31072012.pdf

 

Copenhagen, 2012-07-31 10:03 CEST (GLOBE NEWSWIRE) --  

On 14 May 2012, ALK-Abelló A/S ("ALK") initiated a share buy-back programme, cf. company announcement No. 14/2012. According to the programme, ALK will in the period from 15 May 2012 to 4 February 2013 purchase own shares for a maximum amount of DKK 75 million and no more than 200,000 shares corresponding to 2.0% of the current share capital of ALK. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 2273/2003 of 22 December 2003 and thus ALK will publish the accumulated share buy-back under the programme every week.

The following transactions have been made under the programme:
 

 No of shares bought backAverage transaction priceAmount (DKK)
Accumulated, last announcement
27,373
   
10,032,463
24 July 2012 276 383.87 105,948
25 July 2012 412 382.60 157,632
26 July 20120 0.00 0
27 July 20120 0.00 0
30 July 2012 975 389.71 379,967
Accumulated under the programme
29,036
 
367.68
 
10,676,010


As of today, ALK's total holding of own shares is 386,753 shares of a nominal value of DKK 10, corresponding to 3.8% of the total number of issued shares of 10,128,360.
 

ALK-Abelló A/S
 

Jens Bager
President and CEO
 

For further information please contact:
Per Plotnikof, Investor Relations Director, tel. +45 4574 7527

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved